MedICAL ADVOCATES
Children
  HIV Drug Clinical Trials
CNAA3006
P(2)C(2))
PACTG 144
 PACTG 152
 PACTG 273    
PACTG 338
PACTG 356
 PACTG 377
 PACTG 382
 PACTG 377
PENTA 5

Pediatric Spectrum of HIV Disease
PACTG Multiple Study Data
Italian National AIDS Registry







 
Pediatric HIV Drug Main Page Pediatric HIV Main Page Home Page

Last Update:  March 20, 2015    
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

CNAA3006
               

       Journal Papers, Abstracts, and Commentaries
  A randomized, double-blind study of triple nucleoside therapy of abacavir, l
amivudine, and zidovudine versus lamivudine and zidovudine in previously
treated human immunodeficiency virus type 1-infected children.
The CNAA3006 Study Team. Saez-Llorens X, Nelson RP Jr,
Emmanuel P, et al.
Pediatrics 2001 Jan;107(1):E4 
Abstract		  
P(2)C(2))
               

        Journal Papers, Abstracts, and Commentaries

  Human immunodeficiency virus-related mortality in infants and children: data f
rom the pediatric pulmonary and cardiovascular complications of vertically
transmitted HIV (P(2)C(2)) Study.
Langston C, Cooper ER, Goldfarb J,  et al.
Pediatrics 2001 Feb;107(2):328-38
Abstract

 Maternal and infant factors associated with failure to thrive in children with
vertically transmitted human immunodeficiency virus-1 infection: the prospective,
P2C2 human immunodeficiency virus multicenter study.
Miller TL, Easley KA, Zhang W, et al.
Pediatrics 2001 Dec;108(6):1287-96
 Abstract		  
PACTG 144
 

       Journal Papers, Abstracts, and Commentaries

  Effect of food and pharmacokinetic variability on didanosine systemic exposure
in HIV-infected children
Pediatric AIDS Clinical Trials Group Protocol 144 Study Team. Stevens RC, Rodman 
JH, Yong  FH, et al
AIDS Res Hum Retroviruses 2000 Mar 20;16(5):415-21
Abstract
PACTG 152
 

       Journal Papers, Abstracts, and Commentaries  

Predicting HIV disease progression in children using measures of
neuropsychological and neurological functioning.
Pediatric AIDS clinical trials 152 study team. Pearson DA, McGrath NM,
Nozyce M, et al
Pediatrics 2000 Dec;106(6):E76
Abstract

PACTG 273
 

       Journal Papers, Abstracts, and Commentaries  

Use of human immunodeficiency virus (HIV) human hyperimmune 
immunoglobulin in HIV type 1-infected children
(Pediatric AIDS clinical trials group protocol  273).
Stiehm ER, Fletcher CV, Mofenson LM, et al.
J Infect Dis 2000 Feb;181(2):548-54
Abstract
PACTG 338
 

       Journal Papers, Abstracts, and Commentaries 

  Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced
HIV-infected children:
a  randomized controlled trial.
Pediatric AIDS Clinical Trials Group 338 Study Team. Nachman SA, Stanley K, 
Yogev R, et al.
JAMA 2000 Jan 26;283(4):492-8
Abstract		  
PACTG 351
 

       Journal Papers, Abstracts, and Commentaries  

  Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected
children:  phase 1/2 study.
The Pediatric AIDS Clinical Trials Group Protocol 351 Study Team.
Shearer WT, Israel RJ, Starr S, et al.
J Infect   Dis   2000 Dec;182(6):1774-9
 Abstract		  
PACTG 356
 

       Journal Papers, Abstracts, and Commentaries  

  Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants.
Capparelli EV, Sullivan JL, Mofenson L, et al.
 Pediatric Infectious Disease Journal 2001; 20:746-751.
Abstract
PACTG 377
 

        Journal Papers, Abstracts, and Commentaries

  Combination nucleoside analog reverse transcriptase inhibitor(s) plus
nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced
HIV-infected children week 24 results of a randomized controlled  trial- 
PACTG 377.
Pediatric AIDS Clinical Trials Group 377  Study Team. Wiznia A, Stanley K,
Krogstad P,  et al.  
AIDS Res Hum Retroviruses 2000 Aug   10;16(12):1113-21
 Abstract		  
PACTG 382
 

Journal Papers, Abstracts, and Commentaries

  Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-
transcriptase inhibitors in children infected with human immunodeficiency
virus type 1.
Pediatric AIDS Clinical Trials Group 382 Team. Starr SE, Fletcher CV,
Spector SA, et al.
N Engl J Med. 1999 Dec 16;341(25):1925-6.
Abstract		  
PACTG Multiple Study Data
 

       Journal Papers, Abstracts, and Commentaries

 

Correlates of opportunistic infections in children infected with the human
immunodeficiency virus managed before highly active antiretroviral therapy.
The Pediatric AIDS Clinical Trials Group Protocol Teams 051, 128, 138,
144, 152, 179, 190, 220, 240, 245, 254,300 and 327.
Dankner WM, Lindsey JC, Levin MJ.
Pediatr Infect Dis J 001 Jan;20(1):40-8
 Abstract

Treatment-mediated changes in human immunodeficiency virus (HIV) type 1
RNA and CD4 cell counts as predictors of weight growth failure, cognitive
decline, and survival in HIV-infected children.
Lindsey JC, Hughes MD, McKinney RE , et al.
J  Infect Dis 2000 Nov;182(5):1385-93
Abstract

  
Italian National AIDS Registry
 

       Journal Papers, Abstracts, and Commentaries

  Reduction in mortality with availability of antiretroviral therapy for children
with perinatal HIV-1 infection. Italian Register for HIV Infection in Children
and the Italian National AIDS Registry.
de Martino M, Tovo PA, Balducci M, et al.
JAMA 2000 Jul 12;284(2):190-7
Abstract		  
Pediatric Spectrum of HIV Disease Project
 

       Journal Papers, Abstracts, and Commentaries
  Lack of definitive severe mitochondrial signs and symptoms among deceased
HIV-uninfected and HIV-indeterminate children <or = 5 years of age, Pediatric
Spectrum of HIV Disease Project . USA.
Dominguez K, Bertolli J, Fowler M, et al.
Ann N Y Acad Sci 2000 Nov;918:236-46
Abstract
PENTA 5
 

       Journal Papers, Abstracts, and Commentaries

  Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-
infected children in the PENTA 5 trial.
Gibb DM, Goodall RL, Giacomet V, et al.
Pediatr Infect Dis J 2003 Jan;22(1):56-62
 Abstract

'Impact of Human Immunodeficiency Virus Type 1 Subtypes on Virologic Response
and Emergence of Drug Resistance among Children in the Paediatric European
Network for Treatment of AIDS (PENTA) 5 Trial.
Pillay D, Walker AS, Gibb DM,  et al.
J Infect Dis 2002 Sep 1;186(5):617-25
Abstract

Increased thymic output after initiation of antiretroviral therapy in human i
mmunodeficiency virus type 1-infected children in the Paediatric European Network
for Treatment of AIDS (PENTA) 5 Trial.
De Rossi A, Walker AS, Klein N, et al.
 J Infect Dis 2002 Aug 1;186(3):312-20
 Abstract

 PENTA guidelines for the use of antiretroviral therapy in paediatric HIV infection.
Pediatric European Network for Treatment of AIDS.
Sharland M, di Zub GC, Ramos JT, et al.
HIV Med 2002 Jul;3(3):215-26
 Abstract

Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens
with and without nelfinavir in children with HIV-1 who have not previously been
treated: the PENTA 5 randomised trial.
Paediatric European Network for Treatment of AIDS (PENTA).
 Lancet 2002 Mar 2;359(9308):733-40
 Abstract

T-cell re-population in HIV-infected children on highly active anti-retroviral therapy
(HAART).
King DJ, Gotch FM, Larsson-Sciard EL. et al
 Clin Exp Immunol 2001 Sep;125(3):447-54
 Abstract

Current evidence for the use of paediatric antiretroviral therapy--a PENTA
analysis. Paediatric European Network for the Treatment of AIDS Steering
Committee.
Sharland M, Gibb D, Giaquinto C. et al.
Eur J Pediatr 2000 Sep;159(9):649-56
 Abstract

  

Pediatric HIV Drug Main Page Pediatric HIV Main Page Home Page

Photographer: Lutheran World Relief  Photo courtesy of M/MC Photoshare at www.jhuccp.org/mmc 
and  is  protected by current copyright law 
Pediatric Internet Resource Center
 HIV Drug  Clinical Trials